- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
Novartis Acquires Avrobio’s $88M Gene Therapy
Purchase leaves biotech’s remaining assets on the table.
Novartis, a global healthcare company, has officially reached an agreement with Avrobio, a biotech organization, to acquire AVR-RD-04, an investigational hematopoietic stem cell gene therapy program for the treatment of the rare genetic condition cystinosis. Per the deal, Novartis will pay $87.5 million without committing milestones or royalties to land the clinical-phase asset. This announcement comes after an initial report of the healthcare company preparing for a full takeover.
The deal represents pressure currently facing Avrobio. With its stock trading below $1 in recent months, the biotech’s ability to raise more money from investors is limited, leading it to identify the Novartis deal as a way to boost its bank balance while narrowing its pipeline.
Reference: Novartis to buy Avrobio gene therapy for $88M, leaving rest of the biotech on the shelf. May 22, 2023/ Fierce Biotech
Trends in Continuing Medical Education
April 12th 2024Elliott Yoo, Senior Media Strategist at epocrates, takes a closer look at the trends in CME consumption and what the future of medical education will be – from the priorities for physicians as they juggle learning with patient care, to what type of activities resonate most with prescribers.
Transforming Cancer Care: Data, AI, and Patient-Centered Care
July 20th 2023Join us as Mohit Manrao, SVP and head of US oncology at AstraZeneca, shares his patient-centered approach to transforming cancer care, bridging the gap between innovative science and tangible patient outcomes across all populations on a global scale.
